A phase 1 clinical trial of IM-3050
Latest Information Update: 25 Mar 2025
At a glance
- Drugs IM 3050 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 25 Mar 2025 New trial record
- 19 Mar 2025 According to the Immunome Media Release, company expects to initiate this clinical trial in the second half of 2025.